{"id":"optimal-therapy-for-cardiaca-failure","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of amputations"},{"rate":"null","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"5-10%","effect":"Hypotension"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL521875","moleculeType":"Small molecule","molecularWeight":"460.53"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, the drug decreases glucose levels in the blood, which can help to reduce blood pressure and improve cardiovascular outcomes in patients with heart failure. This mechanism is thought to be beneficial in reducing the risk of hospitalization and mortality in patients with heart failure.","oneSentence":"This drug works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:24:34.348Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Heart failure with reduced ejection fraction"}]},"trialDetails":[{"nctId":"NCT00333827","phase":"PHASE3","title":"Cell Therapy In Dilated Cardiomyopathy","status":"COMPLETED","sponsor":"Ministry of Health, Brazil","startDate":"2006-01","conditions":"Dilated Cardiomyopathy","enrollment":115}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":133,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"optimal therapy for cardiaca failure","genericName":"optimal therapy for cardiaca failure","companyName":"Ministry of Health, Brazil","companyId":"ministry-of-health-brazil","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This drug works by inhibiting the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, reducing glucose reabsorption and promoting its excretion in the urine. Used for Atrial fibrillation for stroke prevention, Heart failure with reduced ejection fraction.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}